Tag: U.S. Congress
FDA Continues Public Comment Period on CBD ‘Indefinitely’
WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) on Wednesday published a report in response to the U.S. Congress’ request for guidelines...
FDA, FTC Take Action on CBD-Infused Products Prior to Public Comments
WASHINGTON, D.C.–Action by the Food and Drug Administration (FDA) on the regulation of CBD-infused products seems imminent, after recent events may signal new developments...
